Prostaglandin D2
(Synonyms: 前列腺素D2,PGD2) 目录号 : GC18232A major prostaglandin produced by mast cells
Cas No.:41598-07-6
Sample solution is provided at 25 µL, 10mM.
Prostaglandin D2 (PGD2) is the major eicosanoid product of mast cells and is released in large quantities during allergic and asthmatic anaphylaxis.[1] Mastocytosis patients produce excessive amounts of PGD2, which causes vasodilation, flushing, hypotension, and syncopal episodes.[1] PGD2 is also produced in the brain via an alternative pathway involving a soluble, secreted PGD-synthase also known as β-trace.[2],[3] In the brain, PGD2 produces normal physiological sleep and lowering of body temperature.[2],[3] Further pharmacological actions include inhibition of platelet aggregation and relaxation of vascular smooth muscle.[4] PGD2 inhibits human ovarian tumor cell proliferation with an IC50 of 6.8 µM.[5]
前列腺素D2 (PGD2) 是肥大细胞的主要花生四烯酸产物,在过敏性和哮喘性过敏反应期间大量释放。[1] 肥大细胞增生症患者产生过多的 PGD2,引起血管扩张、潮红、低血压和晕厥等症状。[1] PGD2 也通过一种可溶性分泌的 PGD 合成酶 (也称为β-痕迹) 的另一途径在大脑中产生。[2],[3] 在大脑中,PGD2 产生正常的生理性睡眠和降低体温。[2],[3] 进一步的药理作用包括抑制血小板聚集和松弛血管平滑肌。[4] PGD2 对人卵巢肿瘤细胞的增殖具有抑制作用,其 IC50 值为 6.8 µM。[5]
Reference:
[1]. Roberts, L.J., II, and Sweetman, B.J. Metabolic fate of endogenously synthesized prostaglandin D2 in a human female with mastocytosis. Prostaglandins 30(3), 383-400 (1985).
[2]. Hayaishi, O. Sleep-wake regulation by prostaglandins D2 and E2. J. Biol. Chem. 263(29), 14593-14596 (1988).
[3]. Onoe, H., Ueno, R., Fujita, I., et al. Prostaglandin D2, a cerebral sleep-inducing substance in monkeys. Proc. Natl. Acad. Sci. U.S.A. 85(11), 4082-4086 (1988).
[4]. Giles, H., and Leff, P. The biology and pharmacology of PGD2. Prostaglandins 35(2), 277-300 (1988).
[5]. Kikuchi, Y., Kita, T., Hirata, J., et al. Preclinical studies of antitumor prostaglandins by using human ovarian cancer cells. Cancer Metastasis Rev. 13(3-4), 309-315 (1994).
Cas No. | 41598-07-6 | SDF | |
别名 | 前列腺素D2,PGD2 | ||
化学名 | 9α,15S-dihydroxy-11-oxo-prosta-5Z,13E-dien-1-oic acid | ||
Canonical SMILES | CCCCCC(O)/C=C/[C@H]1C(=O)CC(O)C1C/C=C\CCCC(=O)O | ||
分子式 | C20H32O5 | 分子量 | 352.5 |
溶解度 | 50mg/mL in ethanol or DMSO or DMF | 储存条件 | Store at -20°C, stored under nitrogen |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.8369 mL | 14.1844 mL | 28.3688 mL |
5 mM | 0.5674 mL | 2.8369 mL | 5.6738 mL |
10 mM | 0.2837 mL | 1.4184 mL | 2.8369 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet